 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen without rabies immune globulin in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen. 